Eli Lilly (LLY) Long-Term Investments (2016 - 2025)
Eli Lilly (LLY) has disclosed Long-Term Investments for 17 consecutive years, with $2.8 billion as the latest value for Q4 2025.
- For the quarter ending Q4 2025, Long-Term Investments fell 12.87% year-over-year to $2.8 billion, compared with a TTM value of $2.8 billion through Dec 2025, down 12.87%, and an annual FY2025 reading of $2.8 billion, down 12.87% over the prior year.
- Long-Term Investments was $2.8 billion for Q4 2025 at Eli Lilly, roughly flat from $2.8 billion in the prior quarter.
- Across five years, Long-Term Investments topped out at $3.5 billion in Q2 2021 and bottomed at $2.6 billion in Q3 2022.
- Average Long-Term Investments over 5 years is $3.0 billion, with a median of $3.0 billion recorded in 2022.
- The sharpest move saw Long-Term Investments soared 50.44% in 2021, then decreased 25.55% in 2022.
- Year by year, Long-Term Investments stood at $3.2 billion in 2021, then decreased by 9.67% to $2.9 billion in 2022, then grew by 5.18% to $3.1 billion in 2023, then grew by 5.37% to $3.2 billion in 2024, then dropped by 12.87% to $2.8 billion in 2025.
- Business Quant data shows Long-Term Investments for LLY at $2.8 billion in Q4 2025, $2.8 billion in Q3 2025, and $3.2 billion in Q2 2025.